MEMORANDUM


TO: Arturo Castillo (PM Team #17)
Registration Division (TS-767c)

FROM: Pamela M. Hurley, Toxicologist
Section II, Toxicology Branch
Hazard Evaluation Division (TS-769c)

THRU: Edwin R. Budd, Section Head
Section II, Toxicology Branch
Hazard Evaluation Division (TS-769c)

Record No. 170855

Sumitomo Chemical Company, Ltd. has submitted a chronic/oncogenicity study on Pyranin Forte in response to a data call-in notice from the USEPA. The Toxicology Branch (TB) is in the process of reviewing the submitted study. In order to complete the review, TB requests that the registrant submit signature pages for the study (see attachments). Neither the study nor the Quality Assurance pages were signed by the individuals responsible for the study.

Attachments (2)
Study requested by:
Sumitomo Chemical Co., Ltd., Osaka city

Study entrusted to:
Daiyu-Kai Institute of Medical Science, Ichinomiya city

Date: May 15, 1985

Hisamasa Sato
Representative Director
Study Manager

Date: May 15, 1985

Masayuki Arai
Study director

Date: May 15, 1985

Akihiro Hagiwara
Director of Research Division
Investigator

Date: May 15, 1985

Masayuki Arai
Director of Pathology
Pathological Investigator
Quality Assurance

We inspected the quality and integrity of the data related to Chronic Toxicity and Oncogenicity Study of Pynamin Forte in Rats to establish that the study had been properly performed, and we herewith certify that this report accurately reflects all data related to the study.

May 15, 1985

DAIYU-KAI INSTITUTE OF MEDICAL SCIENCE

Michiko Shibata
Director of Quality Assurance